Mucopolysaccharidosis (MPS) type VI: A case series to assess the efficacy of enzyme replacement therapy and to guide precision-based medicine in the IRISH paediatric cohort
Mucopolysaccharidosis (MPS) type VI: A case series to assess the efficacy of enzyme replacement therapy and to guide precision-based medicine in the IRISH paediatric cohort. // Molecular Genetics and Metabolism Reports. – URL: https://www.sciencedirect.com/science/article/pii/S2214426926000893?dgcid=rss_sd_all
Mucopolysaccharidosis (MPS) type VI: A case series to assess the efficacy of enzyme replacement therapy and to guide precision-based medicine in the IRISH paediatric cohort. Molecular Genetics and Metabolism Reports. https://www.sciencedirect.com/science/article/pii/S2214426926000893?dgcid=rss_sd_all
“Mucopolysaccharidosis (MPS) type VI: A case series to assess the efficacy of enzyme replacement therapy and to guide precision-based medicine in the IRISH paediatric cohort.” Molecular Genetics and Metabolism Reports.
@article{article5459,
title = {Mucopolysaccharidosis (MPS) type VI: A case series to assess the efficacy of enzyme replacement therapy and to guide precision-based medicine in the IRISH paediatric cohort},
journal = {Molecular Genetics and Metabolism Reports},
url = {https://www.sciencedirect.com/science/article/pii/S2214426926000893?dgcid=rss_sd_all}
}
ABSTRACT Generating bioengineered cartilage that recapitulates the depth-dependent phenotype, structure, and function of native articular cartilage remains a challenge. While cartilage is rich in aggrecan and type II collagen, proper...